Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessMersana Therapeutics Enters into Agreement with a Subsidiary of Merck KGaA

Mersana Therapeutics Enters into Agreement with a Subsidiary of Merck KGaA

Add to Favorite
Added to Favorite


Wedbush provided its review on Mersana Therapeutics, Inc. (NASDAQ:MRSN) after the company entered into a research collaboration and commercial license agreement with a subsidiary of Merck KGaA to develop up to two novel STING-agonist ADCs using the company’s immunostimulatory platform.
The company will receive $30 million upfront in addition to up to $800 million in potential milestones and tiered royalties, up to low double-digits, on net sales. As part of the research collaboration, the company will develop the ADC product candidates by combining its immunosynthen platform with proprietary antibodies from Merck KGaA.
The company will handle certain discovery activities and limited preclinical manufacturing/supply, which will be reimbursed by Merck KGaA.

Subscribe to get Latest News Updates

Latest News

You may like more
more

US Dividend ETFs Bask in Investor Attention After Jumbo Fed Rate Cut

Following a substantial interest rate cut by the Federal...

US Recession Likely: Is Soft Landing Wishful Thinking? Insights from BCA Research

As economic indicators fluctuate, the debate over the likelihood...